Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

The one-month return of Eli Lilly and Company (NYSE:LLY) was 6.82%, and its shares gained 19.17% of their value over the last 52 weeks. On March 5, 2025, Eli Lilly and Company (NYSE:LLY) stock closed ...

Eli Lilly (NYSE: LLY ... The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.